Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Sat Dec 16 16:09:24 GMT 2023
by
admin
on
Sat Dec 16 16:09:24 GMT 2023
|
| Source Materials Class | ORGANISM |
| Source Materials Type | VIRUS |
| Source Materials State | LIVE ATTENUATED GENETICALLY MODIFIED |
| Organism Family | Adenoviridae |
| Organism Genus | Mastadenovirus |
| Organism Species | simian mastadenovirus e |
| Author | NONE |
| Infraspecific Type | RECOMBINANT VECTOR |
| Infraspecific Name | ChAdOx1 nCoV-19 |
| Part | WHOLE |
| Record UNII |
B5S3K2V0G8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000016760
Created by
admin on Sat Dec 16 16:09:24 GMT 2023 , Edited by admin on Sat Dec 16 16:09:24 GMT 2023
|
PRIMARY | |||
|
Oxford–AstraZeneca COVID-19 vaccine
Created by
admin on Sat Dec 16 16:09:24 GMT 2023 , Edited by admin on Sat Dec 16 16:09:24 GMT 2023
|
PRIMARY | |||
|
2420395-83-9
Created by
admin on Sat Dec 16 16:09:24 GMT 2023 , Edited by admin on Sat Dec 16 16:09:24 GMT 2023
|
PRIMARY | |||
|
C173021
Created by
admin on Sat Dec 16 16:09:24 GMT 2023 , Edited by admin on Sat Dec 16 16:09:24 GMT 2023
|
PRIMARY | |||
|
DB15656
Created by
admin on Sat Dec 16 16:09:24 GMT 2023 , Edited by admin on Sat Dec 16 16:09:24 GMT 2023
|
PRIMARY | |||
|
B5S3K2V0G8
Created by
admin on Sat Dec 16 16:09:24 GMT 2023 , Edited by admin on Sat Dec 16 16:09:24 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
EXPRESSED PROTEIN->VECTOR |
|
||
|
|
EXPRESSED PROTEIN->VECTOR |
|
||
|
TARGET ORGANISM->VACCINE ANTIGEN |
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis
EFFICACY
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| GENE DELETION | CHIMPANZEE ADENOVIRUS E1 GENE | SK3BO0EB8B | ||||
| INSERTED GENE EXPRESSION VECTOR | SITE_SPECIFIC | UNSPECIFIED SUBSTANCE |
eaa5aa8e
(not in database)
|